Search Result

Results for "

glycemic control

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Dipeptidyl Peptidase (5) Endogenous Metabolite (2) Free Fatty Acid Receptor (1) GCGR (2) GLP Receptor (1) Histone Demethylase (1) Isotope-Labeled Compounds (1) PPAR (2)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (2) Metabolic Disease (13)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3463

Beinaglutide GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-113075

1,5-Anhydrosorbitol	Endogenous Metabolite	Metabolic Disease
1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-105074

Farglitazar GI262570; GI262570X	PPAR	Metabolic Disease
Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

HY-15408

Trelagliptin SYR-472	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-15408A

Trelagliptin succinate SYR-472 succinate	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-164870

FFAR1/FFAR4 agonist-1	Free Fatty Acid Receptor	Metabolic Disease Inflammation/Immunology
FFAR1/FFAR4 agonist-1 (compound 83) is a FFAR1/FFAR4 agonist with the EC₅₀ of 1 nM A and 4nM for FFAR1 and FFAR4, respectively. FFAR1/FFAR4 agonist-1 can be used for study of glycemic control .

HY-N9911

1,5-Anhydro-D-mannitol	Others	Metabolic Disease
1,5-Anhydro-D-mannitol is the analogue of 1,5-Anhydrosorbitol (HY-113075), and can be used as an experimental control. 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-112668B

Retagliptin hydrochloride SP2086 hydrochloride	Others	Others
Retagliptin (SP2086) hydrochloride is a potent inhibitor of beta-amino acids and dipeptidyl peptidase-4 (DPP-4). Retagliptin (SP2086) hydrochloride inhibits type 2 diabetes and improves glycemic control by prolonging the action of intestinal hormones such as glucagon-like peptide-1 (GLP-1) .

HY-162513

DPP-4-IN-10	Dipeptidyl Peptidase	Cardiovascular Disease
DPP-4-IN-10 (compound 1) is a DPP-4 inhibitor. DPP-4-IN-10 is orally active. DPP-4-IN-10 blocks the degradation of GLP-1 and GIP, which may improve glycemic control in type 2 diabetes (T2MD) .

HY-15408AR

Trelagliptin succinate (Standard)	Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin (succinate) (Standard) is the analytical standard of Trelagliptin (succinate). This product is intended for research and analytical applications. Trelagliptin (SYR-472) succinate is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-15408S

Trelagliptin-13C,d3 SYR-472-¹³C,d₃	Isotope-Labeled Compounds Dipeptidyl Peptidase	Metabolic Disease
Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

HY-125156

Dapagliflozin-3-O-β-D-glucuronide BMS-801576	Endogenous Metabolite	Metabolic Disease
Dapagliflozin-3-O-β-D-glucuronide (BMS-801576) is the metabolite of Dapagliflozin (HY-10450), and is formed in the liver and kidney by uridine diphosphate glucuronosyltransferase-1A9 (UGT1A9). Dapagliflozin is a selective inhibitor for SGLT2, that can be used to improve glycemic control and attenuate type 2 diabetes .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

HY-100546

GSK-LSD1	Histone Demethylase	Infection Metabolic Disease Cancer
GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .

Cat. No.	Product Name	Target	Research Area

HY-P3463

Beinaglutide GLP-1 (human)	GCGR	Metabolic Disease Inflammation/Immunology
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P10318

SHR-2042	GLP Receptor	Endocrinology
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113075

1,5-Anhydrosorbitol	Structural Classification Immune System Disorder Classification of Application Fields Source classification Disease markers Endocrine diseases Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides	Endogenous Metabolite
1,5-Anhydrosorbitol is a short-term marker for glycemic control.

HY-N9911

1,5-Anhydro-D-mannitol	Structural Classification Natural Products Styrax obassia Siebold & Zucc. Source classification Styracaceae Plants	Others
1,5-Anhydro-D-mannitol is the analogue of 1,5-Anhydrosorbitol (HY-113075), and can be used as an experimental control. 1,5-Anhydrosorbitol is a short-term marker for glycemic control.

Cat. No.	Product Name	Chemical Structure

HY-15408S

Trelagliptin-13C,d3
Trelagliptin-13C,d3 is a deuterated labeled Trelagliptin . Trelagliptin (SYR-472) is a potent, orally active and highly selective DPP-4 inhibitor with an IC₅₀ of 4 nM. Trelagliptin succinate improves glycemic control in vivo and can be used for the study of type 2 diabetes mellitus (T2DM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

glycemic control

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products